Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System(G-stream) in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

A multicenter, randomized, controlled, superiority clinical trial to evaluate the efficacy and safety of drug-eluting peripheral arterial stent system(G-stream) in the treatment of femoropopliteal artery stenosis or occlusion.

Who May Be Eligible (Plain English)

Who May Qualify: - General Inclusion Criteria: 1. Age from 18 to 80 years, male or female; 2. Patients with Lower extremity peripheral artery disease (PAD); 3. With Rutherford classification between 2 and 5; 4. Patients understand the purpose of the study, voluntary participation of the study, signs the consent form, willing and able to comply with all requirements, and agrees to attend all required follow-up visits; - Angiographic Inclusion Criteria: 5.Single lesions or tandem lesions located in the SFA and/or PPA: 1. Degree of stenosis ≥ 70% and \<100%, Total lesion length ≥ 20 mm and ≤ 250 mm; or 2. Occlusive lesions, total lesion length ≤ 150 mm; or 3. Series of lesions, total lesion length ≤ 250 mm and length of occlusive lesions ≤ 150 mm; 6.Vessel diameter ≥ 3.5 and ≤ 7.5 mm by visual angiographic assessment; 7.Re-entry device reach and cross a target lesion successfully; 8.Residual stenosis after predilation ≤ 50% without dissection characterized as type D or greater; 9. Patent homolateral iliac inflow (stenosis ≤ 50% ) or homolateral iliac inflow lesion received successfully treated i.e., residual stenosis \< 30% after treatment, without severe flow-limiting dissection characterized as type D or greater, without thrombosis, embolism or other serious adverse events; 10.Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (stenosis ≤ 50%) to the ankle or foot before procedure or with planned intervention. Who Should NOT Join This Trial: -General Exclusion Criteria: 1. Wtih vasculitis or Berger disease; 2. With severe coagulation disorders or uncontrolled severe infections, not suitable for intervention procedure; 3. Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, paclitaxel, rapamycin, contrast dye or others; 4. History of distal amputation (above the metatarsal) in the target limb or contralateral limb; ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * General Inclusion Criteria: 1. Age from 18 to 80 years, male or female; 2. Patients with Lower extremity peripheral artery disease (PAD); 3. With Rutherford classification between 2 and 5; 4. Patients understand the purpose of the study, voluntary participation of the study, signs the consent form, willing and able to comply with all requirements, and agrees to attend all required follow-up visits; * Angiographic Inclusion Criteria: 5.Single lesions or tandem lesions located in the SFA and/or PPA: 1. Degree of stenosis ≥ 70% and \<100%, Total lesion length ≥ 20 mm and ≤ 250 mm; or 2. Occlusive lesions, total lesion length ≤ 150 mm; or 3. Series of lesions, total lesion length ≤ 250 mm and length of occlusive lesions ≤ 150 mm; 6.Vessel diameter ≥ 3.5 and ≤ 7.5 mm by visual angiographic assessment; 7.Re-entry device reach and cross a target lesion successfully; 8.Residual stenosis after predilation ≤ 50% without dissection characterized as type D or greater; 9. Patent homolateral iliac inflow (stenosis ≤ 50% ) or homolateral iliac inflow lesion received successfully treated i.e., residual stenosis \< 30% after treatment, without severe flow-limiting dissection characterized as type D or greater, without thrombosis, embolism or other serious adverse events; 10.Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (stenosis ≤ 50%) to the ankle or foot before procedure or with planned intervention. Exclusion Criteria: -General Exclusion Criteria: 1. Wtih vasculitis or Berger disease; 2. With severe coagulation disorders or uncontrolled severe infections, not suitable for intervention procedure; 3. Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, paclitaxel, rapamycin, contrast dye or others; 4. History of distal amputation (above the metatarsal) in the target limb or contralateral limb; 5. Severe renal insufficiency (creatinine \> 221 umol/L); 6. History of local thrombolysis or systemic thrombolysis within 48 hours prior to procedure; 7. History of acute myocardial infarction within 30 days prior to procedure; 8. History of major surgery(i.e., open cardiac operation, open abdominal surgery or open operation for peripheral artery disease) within 30 days prior to procedure; 9. History of alimentary tract hemorrhage within 3 months prior to procedure; 10. History of stroke/cerebrovascular accident (CVA) within 6 months prior to procedure; 11. Life expectancy \<12 months; 12. History of stent, drug-coated balloon or bypass surgery in the target lesion; 13. Use of atherectomy, laser, cryoplasty or other debulking devices in the target lesion during the index procedure; 14. Pregnant, breast feeding, or plan to become pregnant; 15. Current participation in another investigational drug or device clinical study; 16. According to the judgement of the investigator, other situations that are not suitable for enrollment; * Angiographic Exclusion Criteria: 17. Heavily calcified lesions; 18. Presence of aneurysm in the target vessel; 19. Acute or subacute thrombosis of the target vessel; 20. History of graft intervention in the target limb.

Treatments Being Tested

DEVICE

Drug eluting stent

Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.

DEVICE

drug coating balloon

A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.

Locations (1)

Changhai Hospital of Shanghai
Shanghai, Shanghai Municipality, China